{"nctId":"NCT01743989","briefTitle":"A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.","startDateStruct":{"date":"2013-04-15","type":"ACTUAL"},"conditions":["Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)"],"count":620,"armGroups":[{"label":"Nilotinib 24-month treatment","type":"EXPERIMENTAL","interventionNames":["Drug: Nilotinib"]},{"label":"Nilotinib 36-month treatment","type":"EXPERIMENTAL","interventionNames":["Drug: Nilotinib"]},{"label":"Not randomized","type":"EXPERIMENTAL","interventionNames":["Drug: Nilotinib"]}],"interventions":[{"name":"Nilotinib","otherNames":["AMN107"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Confirmed diagnosis of chronic phase Ph+ CML\n* Previous first-line treatment with imatinib for a minimum of 2 years;\n* Patient in complete cytogenetic response;\n\nKey Exclusion Criteria:\n\n* Previous achievement of MR4.0 at study entry;\n* Previous treatment with other target cells inhibitors other than imatinib;\n* Patients with any history of detectable atypical Leukemia transcripts or patients with detectable atypical leukemia transcripts at screening;\n* Previous anticancer agents for Chronic myeloid leukemia other than imatinib except for cytoreduction;\n* Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol;\n* History of other active malignancies within the 5 years prior to study entry with the exception of previous or concomitant basal cell skin cancer and previous carcinoma in situ treated curatively;\n* Patients who have not recovered from prior surgery;\n* Treatment with other investigational agents within 4 weeks of Day 1;\n* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug\n\nOther inclusion/exclusion criteria might apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Remained in Treatment Free Remission (TFR) Without Molecular Relapse 12 Months After Entering the TFR Phase","description":"Number of participants who remained in TFR (≥molecular response (MR) 4.0) without molecular relapse 12 months after entering the TFR phase (without re-starting nilotinib therapy) divided by the number of participants who entered the TFR phase and multiplied by 100.\n\nMolecular relapse during TFR is defined as the loss of major molecular response (MMR), or the confirmed loss of MR4.0 (defined by 3 consecutive tests less than MR4.0 assessed at 3 consecutive visits during TFR phase). Participants dropping out early from the study during the TFR phase were considered as unsuccessful TFR.\n\nConfidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.\n\nMR4.0 is defined as either detectable disease≤0.01% BCR-ABL or undetectable disease in cDNA with≥10,000 ABL transcripts","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.9","spread":null},{"groupId":"OG001","value":"37.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of MMR During the Pre-randomization Induction/Consolidation Phase Among Participants Without That Response at Study Entry","description":"Number of participants who were in MMR during pre-randomization induction/consolidation phase divided by the number of participants without that response at baseline and multiplied by 100.\n\nConfidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.6","spread":null},{"groupId":"OG001","value":"37.5","spread":null},{"groupId":"OG002","value":"29.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"64.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"71.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"77.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"80.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"82.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"85.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"86.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of MMR During the Post-randomization Consolidation Phase Among Participants Without That Response at Study Entry","description":"Number of participants who were in MMR during post-randomization consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm.\n\nConfidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of MR4.0 During the Pre-randomization Induction/Consolidation Phase Among Participants Without That Response at Study Entry","description":"Number of participants who were in MR4.0 during the pre-randomization induction/consolidation phase divided by the number of participants without that response at baseline and multiplied by 100.\n\nConfidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.9","spread":null},{"groupId":"OG001","value":"38.3","spread":null},{"groupId":"OG002","value":"12.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.9","spread":null},{"groupId":"OG001","value":"81.9","spread":null},{"groupId":"OG002","value":"26.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.6","spread":null},{"groupId":"OG001","value":"92.6","spread":null},{"groupId":"OG002","value":"34.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.7","spread":null},{"groupId":"OG001","value":"98.9","spread":null},{"groupId":"OG002","value":"39.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"98.9","spread":null},{"groupId":"OG002","value":"42.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"45.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"48.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"52.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of MR4.0 During the Post-randomization Consolidation Phase Among Participants Without That Response at Study Entry","description":"Number of participants who were in MR4.0 during the post-randomization consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm.\n\nConfidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of MR4.5 During the Pre-randomization Induction/Consolidation Phase Among Participants Without That Response at Study Entry","description":"Number of participants who were in MR4.5 during the pre-randomization induction/consolidation phase divided by the number of participants without that response at baseline and multiplied by 100.\n\nConfidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.1","spread":null},{"groupId":"OG001","value":"17.4","spread":null},{"groupId":"OG002","value":"4.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.5","spread":null},{"groupId":"OG001","value":"38.5","spread":null},{"groupId":"OG002","value":"8.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.8","spread":null},{"groupId":"OG001","value":"54.1","spread":null},{"groupId":"OG002","value":"10.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.6","spread":null},{"groupId":"OG001","value":"65.1","spread":null},{"groupId":"OG002","value":"14.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.8","spread":null},{"groupId":"OG001","value":"76.1","spread":null},{"groupId":"OG002","value":"15.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.5","spread":null},{"groupId":"OG001","value":"80.7","spread":null},{"groupId":"OG002","value":"16.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.3","spread":null},{"groupId":"OG001","value":"84.4","spread":null},{"groupId":"OG002","value":"18.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.0","spread":null},{"groupId":"OG001","value":"89.0","spread":null},{"groupId":"OG002","value":"20.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of MR4.5 During the Post-randomization Consolidation Phase Among Participants Without That Response at Study Entry","description":"Number of participants who were in MR4.5 during the post-randomization consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm.\n\nConfidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of MMR During the Pre-randomization Induction/Consolidation Phase","description":"Number of participants who were in MMR during the pre-randomization induction/consolidation phase divided by the number of enrolled participants and multiplied by 100.\n\nConfidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.8","spread":null},{"groupId":"OG001","value":"86.4","spread":null},{"groupId":"OG002","value":"74.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.2","spread":null},{"groupId":"OG001","value":"91.5","spread":null},{"groupId":"OG002","value":"81.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"90.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"92.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"94.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"95.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"95.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"96.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"96.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of MMR During the Post-randomization Consolidation Phase","description":"Number of participants who were in MMR during the post-randomization consolidation phase divided by the number of enrolled participants and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm.\n\nConfidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of MR4.0 During the Pre-randomization Induction/Consolidation Phase","description":"Number of participants who were in MR4.0 during the pre-randomization induction/consolidation phase divided by the number of enrolled participants and multiplied by 100.\n\nConfidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":null},{"groupId":"OG001","value":"20.3","spread":null},{"groupId":"OG002","value":"6.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.8","spread":null},{"groupId":"OG001","value":"50.8","spread":null},{"groupId":"OG002","value":"18.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.2","spread":null},{"groupId":"OG001","value":"85.6","spread":null},{"groupId":"OG002","value":"31.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.8","spread":null},{"groupId":"OG001","value":"94.1","spread":null},{"groupId":"OG002","value":"38.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.5","spread":null},{"groupId":"OG001","value":"99.2","spread":null},{"groupId":"OG002","value":"43.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.2","spread":null},{"groupId":"OG002","value":"45.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"48.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"52.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"55.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of MR4.0 During the Post-randomization Consolidation Phase","description":"Number of participants who were in MR4.0 during the post-randomization consolidation phase divided by the number of enrolled participants and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm.\n\nConfidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of MR4.5 During the Pre-randomization Induction/Consolidation Phase","description":"Number of participants who were in MR4.5 during the pre-randomization induction/consolidation phase divided by the number of enrolled participants and multiplied by 100.\n\nConfidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":null},{"groupId":"OG001","value":"7.6","spread":null},{"groupId":"OG002","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.3","spread":null},{"groupId":"OG001","value":"23.7","spread":null},{"groupId":"OG002","value":"5.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.2","spread":null},{"groupId":"OG001","value":"43.2","spread":null},{"groupId":"OG002","value":"10.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.7","spread":null},{"groupId":"OG001","value":"57.6","spread":null},{"groupId":"OG002","value":"12.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.3","spread":null},{"groupId":"OG001","value":"67.8","spread":null},{"groupId":"OG002","value":"15.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.7","spread":null},{"groupId":"OG001","value":"78.0","spread":null},{"groupId":"OG002","value":"16.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","spread":null},{"groupId":"OG001","value":"82.2","spread":null},{"groupId":"OG002","value":"18.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.7","spread":null},{"groupId":"OG001","value":"85.6","spread":null},{"groupId":"OG002","value":"19.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null},{"groupId":"OG001","value":"89.8","spread":null},{"groupId":"OG002","value":"21.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of MR4.5 During the Post-randomization Consolidation Phase","description":"Number of participants who were in MR4.5 during the post-randomization consolidation phase divided by the number of enrolled participants and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm.\n\nConfidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Were in MMR During TFR Phase","description":"Number of participants who were in MMR at selected timepoints divided by the number of participants in the TFR phase and multiplied by 100. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase.\n\nConfidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.5","spread":null},{"groupId":"OG001","value":"94.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.9","spread":null},{"groupId":"OG001","value":"80.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.2","spread":null},{"groupId":"OG001","value":"61.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.3","spread":null},{"groupId":"OG001","value":"53.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.4","spread":null},{"groupId":"OG001","value":"46.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null},{"groupId":"OG001","value":"43.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.3","spread":null},{"groupId":"OG001","value":"43.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.7","spread":null},{"groupId":"OG001","value":"42.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.1","spread":null},{"groupId":"OG001","value":"39.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.3","spread":null},{"groupId":"OG001","value":"39.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.3","spread":null},{"groupId":"OG001","value":"39.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.5","spread":null},{"groupId":"OG001","value":"38.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.9","spread":null},{"groupId":"OG001","value":"35.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Were in MR4.0 During the TFR Phase","description":"Number of participants who were in MR4.0 at selected timepoints divided by the number of participants in the TFR phase and multiplied by 100. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase.\n\nConfidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.4","spread":null},{"groupId":"OG001","value":"83.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.0","spread":null},{"groupId":"OG001","value":"56.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.5","spread":null},{"groupId":"OG001","value":"42.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.1","spread":null},{"groupId":"OG001","value":"42.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.8","spread":null},{"groupId":"OG001","value":"41.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.6","spread":null},{"groupId":"OG001","value":"38.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.5","spread":null},{"groupId":"OG001","value":"40.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.3","spread":null},{"groupId":"OG001","value":"38.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.9","spread":null},{"groupId":"OG001","value":"37.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.5","spread":null},{"groupId":"OG001","value":"34.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.6","spread":null},{"groupId":"OG001","value":"38.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3","spread":null},{"groupId":"OG001","value":"32.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":null},{"groupId":"OG001","value":"30.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Were in MR4.5 During the TFR Phase","description":"Number of participants who were in MR4.5 at selected timepoints divided by the number of participants in the TFR phase and multiplied by 100. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase.\n\nConfidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.8","spread":null},{"groupId":"OG001","value":"26.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":null},{"groupId":"OG001","value":"28.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.2","spread":null},{"groupId":"OG001","value":"26.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":null},{"groupId":"OG001","value":"23.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.2","spread":null},{"groupId":"OG001","value":"26.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","spread":null},{"groupId":"OG001","value":"22.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.4","spread":null},{"groupId":"OG001","value":"20.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","spread":null}]}]}]},{"type":"SECONDARY","title":"BCR-ABL Ratio (Expressed as a Percentage) During the Induction/Consolidation Phase","description":"BCR-ABL transcript ratio by international scale (IS) (expressed as a percentage) during the induction/consolidation phase. Participants randomized to Nilotinib 36-month treatment arm had 12-month additional consolidation phase (post-randomization).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1367","spread":"0.55144"},{"groupId":"OG001","value":"0.0633","spread":"0.12790"},{"groupId":"OG002","value":"0.5509","spread":"3.94256"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0106","spread":"0.02660"},{"groupId":"OG001","value":"0.0086","spread":"0.01155"},{"groupId":"OG002","value":"0.0728","spread":"0.22537"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0052","spread":"0.00631"},{"groupId":"OG001","value":"0.0124","spread":"0.05508"},{"groupId":"OG002","value":"0.0530","spread":"0.09587"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0049","spread":"0.00809"},{"groupId":"OG001","value":"0.0046","spread":"0.00544"},{"groupId":"OG002","value":"0.0573","spread":"0.13905"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0044","spread":"0.00611"},{"groupId":"OG001","value":"0.0037","spread":"0.00440"},{"groupId":"OG002","value":"0.0772","spread":"0.56398"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0035","spread":"0.00591"},{"groupId":"OG001","value":"0.0034","spread":"0.00389"},{"groupId":"OG002","value":"0.0669","spread":"0.37209"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0029","spread":"0.00354"},{"groupId":"OG001","value":"0.0034","spread":"0.00409"},{"groupId":"OG002","value":"0.0462","spread":"0.12284"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0028","spread":"0.00319"},{"groupId":"OG001","value":"0.0031","spread":"0.00288"},{"groupId":"OG002","value":"0.0390","spread":"0.08271"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0027","spread":"0.00424"},{"groupId":"OG001","value":"0.0029","spread":"0.00319"},{"groupId":"OG002","value":"0.0325","spread":"0.05140"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.0089","spread":"0.06119"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.0111","spread":"0.08672"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.0025","spread":"0.00439"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.0025","spread":"0.00338"}]}]}]},{"type":"SECONDARY","title":"BCR-ABL Ratio (Expressed as a Percentage) During the TFR Phase","description":"BCR-ABL/control gene (ABL) transcript ratio by international scale (IS) (expressed as a percentage) during the TFR phase. BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes.\n\nParticipants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0042","spread":"0.00621"},{"groupId":"OG001","value":"0.0074","spread":"0.02130"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1162","spread":"0.35606"},{"groupId":"OG001","value":"0.2122","spread":"0.99372"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3774","spread":"9.71909"},{"groupId":"OG001","value":"0.4754","spread":"1.84649"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2667","spread":"0.80336"},{"groupId":"OG001","value":"0.2506","spread":"0.91197"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1740","spread":"0.76123"},{"groupId":"OG001","value":"0.0801","spread":"0.26739"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2219","spread":"1.51808"},{"groupId":"OG001","value":"0.1095","spread":"0.66322"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0075","spread":"0.01403"},{"groupId":"OG001","value":"0.0042","spread":"0.00742"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0062","spread":"0.01295"},{"groupId":"OG001","value":"0.0039","spread":"0.00680"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0047","spread":"0.00665"},{"groupId":"OG001","value":"0.0027","spread":"0.00357"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0030","spread":"0.00317"},{"groupId":"OG001","value":"0.0043","spread":"0.00555"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0030","spread":"0.00384"},{"groupId":"OG001","value":"0.0027","spread":"0.00330"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0036","spread":"0.00484"},{"groupId":"OG001","value":"0.0041","spread":"0.00495"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0077","spread":"0.02910"},{"groupId":"OG001","value":"0.0047","spread":"0.00691"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0024","spread":"0.00246"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0023","spread":"0.00281"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0079","spread":"0.02376"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0041","spread":"0.00767"}]}]}]},{"type":"SECONDARY","title":"BCR-ABL Ratio (Expressed as a Percentage) During the Nilotinib Re-treatment Phase","description":"BCR-ABL/control gene (ABL) transcript ratio by international scale (IS) (expressed as a percentage) during the nilotinib re-treatment phase. BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8246","spread":"2.39596"},{"groupId":"OG001","value":"0.6301","spread":"0.74388"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6276","spread":"2.34231"},{"groupId":"OG001","value":"0.3112","spread":"0.60279"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0311","spread":"0.07265"},{"groupId":"OG001","value":"0.0131","spread":"0.02359"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0095","spread":"0.03296"},{"groupId":"OG001","value":"0.0070","spread":"0.01330"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0259","spread":"0.17766"},{"groupId":"OG001","value":"0.0065","spread":"0.01099"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0088","spread":"0.03190"},{"groupId":"OG001","value":"0.0047","spread":"0.00839"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0061","spread":"0.01322"},{"groupId":"OG001","value":"0.0045","spread":"0.01176"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0105","spread":"0.05205"},{"groupId":"OG001","value":"0.0039","spread":"0.00581"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0051","spread":"0.01699"},{"groupId":"OG001","value":"0.0031","spread":"0.00342"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0038","spread":"0.00756"},{"groupId":"OG001","value":"0.0014","spread":"0.00197"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0033","spread":"0.00439"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0113","spread":"0.04446"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0029","spread":"0.00541"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0005","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS) During the TFR Phase of the Study.","description":"PFS is defined as the time from the date of start of the nilotinib TFR phase to the date of acelerated phase/blast crisis (AP/BC) or death, whichever came first. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotini 24-month treatment arm had a maximum of 36 months of TFR phase.\n\nPatients not known to have recurred or died on or before the cut-off date for PFS analysis were censored at the date of their last assessment (cytogenetic, hematology or extramedullary) for patients who were on study, and at the date of last contact for patients who were in follow-up.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment -Free Survival (TFS) During the TFR Phase of the Study","description":"TFS is defined as the time from the start of the TFR phase to the date of the earliest of the following: loss of MMR, confirmed loss of MR4.0,re-start of nilotinib treatment, progression to AP/BC, or death from any cause. Patients not known to have had any of the events on or before the cut-off date were censored at the earlier of the date of their last assessment for patients who were still on study and the date of last contact for patients who were in follow-up. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1%BCR-ABL.\n\nMR4.0 is defined as either detectable disease ≤0.01%BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"4.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) Rate During the TFR Phase of the Study.","description":"OS is defined as the time from start of the TFR phase to the time of death due to any cause. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotini 24-month treatment arm had a maximum of 36 months of TFR phase.\n\nFor participants without any event on or before the cut-off date, survival time will be censored at the date of their last assessment for patients who are still on study, and at the date of last contact for patients who are in follow-up.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"POST_HOC","title":"All Collected Deaths","description":"Deaths on-treatment were collected during the induction/consolidation phase (from the first dose of study drug to 30 days after study treatment discontinuation, assessed up to 24 months for Nilotinib 24-month treatment arm and Not randomized, and up to 36 months for Nilotinib 36-month treatment arm) and during the re-treatment phase (from the start date of the re-treatment phase to 30 days after study treatment discontinuation, assessed up to 36 months for Nilotinib 24-month treatment arm and up to 24 months for Nilotinib 36-month treatment arm).\n\nTotal deaths were collected from first dose of study drug until end of study, up to maximum duration of 5 years","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":33,"n":120},"commonTop":["Hypercholesterolaemia","Pruritus","Rash","Hypertension","Lipase increased"]}}}